2022
The Multiple Sclerosis Prodrome: Evidence to Action
Tremlett H, Munger KL, Makhani N. The Multiple Sclerosis Prodrome: Evidence to Action. Frontiers In Neurology 2022, 12: 761408. PMID: 35173664, PMCID: PMC8841819, DOI: 10.3389/fneur.2021.761408.Peer-Reviewed Original ResearchMultiple sclerosisProdromal phaseEarly recognitionImproved disease courseProdromal multiple sclerosisImmune-mediated diseasesMultiple sclerosis prodromeEarly disease managementDisease courseProdromal featuresDefinitive diagnosisClassical diseaseGeneral populationMS prodromeDisease preventionProdromeMajor long-term implicationsDisease managementPrognosisDiseaseLong-term implicationsPreventionSclerosisEvidenceSymptoms
2021
The multiple sclerosis prodrome
Makhani N, Tremlett H. The multiple sclerosis prodrome. Nature Reviews Neurology 2021, 17: 515-521. PMID: 34155379, PMCID: PMC8324569, DOI: 10.1038/s41582-021-00519-3.Peer-Reviewed Original ResearchConceptsMultiple sclerosisMS prodromeProdromal phaseCause of MSLong-term disabilityMultiple sclerosis prodromePutative risk factorsProfound clinical implicationsRelapse rateClinical featuresEarly recognitionInflammatory diseasesRisk factorsEarly initiationProdromePotential biomarkersClinical implicationsTypical symptomsDiseaseSymptomsFuture initiativesSclerosisMajor knowledge gapsBiomarkersPossible duration